DIABETES VACCINE MARKET ANALYSIS

Name: Diabetes Vaccine Market News
Creator: Coherent Market Insights
License: https://www.coherentmarketinsights.com/privacy-policy

Diabetes Vaccine Market, by Age Group (Up to 20 Years of Age and 20 Years and above), by End User (Hospitals and Clinics) and by Geography - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2022-2028

Developments in the diabetes vaccine market

Imcys— a Belgium-based biotech company— announced plans to commence its clinical trial in 2018 for new diabetes vaccine to treat type 1 diabetes. It uses modified peptides called imotopes, which spurs specific type of immune cell to kill immune cells that work on the insulin producing beta cells.
Moreover, in 2017, Massachusetts General Hospital Immunobiology Laboratory presented findings of clinical trial at 75th Scientific Sessions of the American Diabetes Association, related to use of BCG vaccine to treat autoimmune response in type 1 diabetes. BCG vaccine could induce a permanent gene expression that restores regulatory T cells, thereby preventing the immune system attack, which is observed in type 1 diabetes. It is currently under phase two clinical trial.